Thymosin α1 therapy subsequent to radical hepatectomy in patients with hepatitis B virus-associated hepatocellular carcinoma: A retrospective controlled study

Oncology Letters

Volumn 12, Issue 5, 2016, Pages 3513-3518

  Liang, Yong Rong ^a,b   Guo, Zhe ^c   Jiang, Jing Hang ^d   Xiang, Bang De ^a   Li, Le Qun ^a  

^a GUANGXI MEDICAL UNIVERSITY   (China)

^b The Second People s Hospital of Qinzhou   (China)

^c CENTRAL HOSPITAL OF WUHAN   (China)

^d The Center of Cancer Prevention   (China)

Author keywords

Hepatocellular carcinoma; Overall survival; Propensity score matching; Recurrence free survival rate; Thymosin 1

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALPHA FETOPROTEIN; BILIRUBIN; THYMOSIN ALPHA1;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER FUNCTION; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OVERALL SURVIVAL; PROTHROMBIN TIME; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; SCORING SYSTEM; TREATMENT OUTCOME;

EID: 84990041371     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2016.5121     Document Type: Article

References (21)

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin 65: 87-108, 2015.
2. Guo Z, Zhong JH, Jiang JH, Zhang J, Xiang BD and Li LQ: Comparison of survival of patients with BCLC stage a hepatocellular carcinoma after hepatic resection or transarterial chemoembolization: A propensity score based analysis. Ann Surg Oncol 21: 3069-3076, 2014.
3. Li T, Fan J, Qin LX, Zhou J, Sun HC, Qiu SJ, Ye QH, Wang L and Tang ZY: Risk factors, prognosis and management of early and late intrahepatic recurrence after resection of primary clear cell carcinoma of the liver. Ann Surg Oncol 18: 1955-1963, 2011.
4. Arnaoutakis DJ, Mavros MN, Shen F, Alexandrescu S, Firoozmand A, Popescu I, Weiss M, Wolfgang CL, Choti MA and Pawlik TM: Recurrence patterns and prognostic factors in patients with hepatocellular carcinoma in noncirrhotic liver: A Multi-Institutional analysis. Ann Surg Onco 21: 147-154, 2014.
5. Forner A, Llovet J and Bruix J: Hepatocellular carcinoma. Lancet 379: 1245-1255, 2012.
6. Zhong JH, Ma L, Wu LC, Zhao W, Yuan WP, Wu FX, Zhang ZM, Huang S, You XM and Li LQ: Adoptive immunotherapy for postoperative hepatocellular carcinoma: A systematic review. Int J Clin Pract 66: 21-27, 2012.
7. Lee SC: Prognostic biomarkers for prediction of recurrence of hepatocellular carcinoma: Current status and future prospects. World J Gastroenterol 20: 3112-3124, 2014.
8. You J, Zhuang L, Cheng HY, Yan SM, Yu L, Huang JH, Tang BZ, Huang ML, Ma YL and Chongsuvivatwong V, et al: Efficacy of thymosin alpha 1 and interferon alpha in treatment of chronic viral hepatitis B: A randomized controlled study. World J Gastroenterol 12: 6715-6721, 2006.
9. Kim BH, Lee YJ, Kim W, Yoon JH, Jung EU, Park SJ, Kim YJ and Lee HS: Efficacy of thymosin α-1 plus peginterferon α-2a combination therapy compared with peginterferon α-2a monotherapy in HBeAg positive chronic hepatitis B: A prospective, multicenter, randomized, open-label study. Scand J Gastroenterol 47: 1048-1055, 2012.
10. Matteucci C, Minutolo A, Sinibaldi-Vallebona P, Palamara AT, Rasi G, Mastino A and Garaci E: Transcription profile of human lymphocytes following invitro treatment with thymosin alpha-1. Ann N Y Acad Sci 1194: 6-19, 2010.
11. Cheng SQ, Wu MC, Chen H, Shen F, Yang JH, Zhao YX and Mo ZW: Influence of thymosin α 1 on postoperative recurrence of primary liver cancer. Chin J Hepatobil Surg 10: 592-593, 2004 (In Chinese).
12. Palmieri G, Biondi E, Morabito A, Rea A and Bianco A: Could thymostimulin prevent hepatocellular carcinoma occurrence in patients with liver cirrhosis? Oncol Rep 3: 655-656, 1996.
13. Zhong J, Ke Y, Gong W, Xiang BD, Ma L, Ye XP, Peng T, Xie GS and Li LQ: Hepatic resection associated with good survival for selected patients with intermediate and advanced-stage hepatocellular carcinoma. Ann Surg 260: 329-340, 2014.
14. Zhong JH, Xiang BD, Gong WF, Ke Y, Mo QG, Ma L, Liu X and Li LQ: Comparison of long-term survival of patients with BCLC stage B hepatocellular carcinoma after liver resection or transarterial chemoembolization. PLoS One 8: e68193, 2013.
15. Forner A, Reig ME, de Lope CR and Bruix J: Current strategy for staging and treatment: The BCLC update and future prospects. Semin Liver Dis 30: 61-74, 2010.
16. Chun JM, Kwon HJ, Sohn J, Kim SG, Park JY, Bae HI, Yun YK and Hwang YJ: Prognostic factors after early recurrence in patients who underwent curative resection for hepatocellular carcinoma. J Surg Oncol 103: 148-151, 2011.
17. Poon RT: Differentiating early and late recurrences after resection of HCC in cirrhotic patients: Implications on surveillance, prevention, and treatment strategies. Ann Surg Oncol 16: 792-794, 2009.
18. Garaci E, Pica F, Serafino A, Balestrieri E, Matteucci C, Moroni G, Sorrentino R, Zonfrillo M, Pierimarchi P and Sinibaldi-Vallebona P: Thymosin α 1 and cancer: Action on immune effector and tumor target cells. Ann N Y Acad Sci 1269: 26-33, 2012.
19. Nitta H, Beppu T, Imai K, Hayashi H, Chikamoto A and Baba H: Adjuvant hepatic arterial infusion chemotherapy after hepatic resection of hepatocellular carcinoma with macroscopic vascular invasion. World J Surg 37: 1034-1042, 2013.
20. Zhong JH, Li H, Li LQ, You XM, Zhang Y, Zhao YN, Liu JY, Xiang BD and Wu GB: Adjuvant therapy options following curative treatment of hepatocellular carcinoma: A systematic review of randomized trials. Eur J Surg Oncol 38: 286-295, 2012.
21. Wu C, Chen Y, Ho HJ, Hsu YC, Kuo KN, Wu MS and Lin JT: Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection. JAMA 308: 1906-1913, 2012.